Iloperidone Phase III Clinical Data Demonstrate Efficacy And Favorable Safety And Tolerability Profile

Titan Pharmaceuticals, Inc. (AMEX: TTP) announced that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 20th, 2007